Social Europe

politics, economy and employment & labour

  • Projects
    • Corporate Taxation in a Globalised Era
    • US Election 2020
    • The Transformation of Work
    • The Coronavirus Crisis and the Welfare State
    • Just Transition
    • Artificial intelligence, work and society
    • What is inequality?
    • Europe 2025
    • The Crisis Of Globalisation
  • Audiovisual
    • Audio Podcast
    • Video Podcasts
    • Social Europe Talk Videos
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Shop
  • Membership
  • Ads
  • Newsletter

How to develop a Covid-19 vaccine for all

by Mariana Mazzucato and Els Torreele on 29th April 2020 @MazzucatoM

Share on TwitterShare on FacebookShare on LinkedIn

Ensuring no one is left behind requires not just unprecedented collective investment but a very different approach to innovation.

Covid-19 vaccine
Mariana Mazzucato

In the early weeks of 2020, it started to dawn on people that Covid-19 could be the long-dreaded but expected ‘Disease X’—a global pandemic caused by an unknown virus. Three months later, the majority of the world’s population is in lockdown, and it is clear that we are only as healthy as our neighbours—locally, nationally and internationally.

Strong health systems, adequate testing capacity and an effective, universally available vaccine will be key to protecting societies from Covid-19. But ensuring that no one is left behind requires not just unprecedented collective investment, but also a very different approach.

Covid-19 vaccine
Els Torreele

Researchers at universities and companies around the world are racing to develop a vaccine. And current progress is encouraging: 73 vaccine candidates are actively being explored or are in preclinical development, while five already have entered clinical trials.

Public investment

These massive efforts are possible only because of substantial public investment, including by the US National Institutes of Health and the Coalition for Epidemic Preparedness Innovations (CEPI). The latter, a publicly funded non-profit organisation, was established after the 2014-16 west-African Ebola epidemic to drive research and development of vaccines that could be deployed during disease outbreaks.

CEPI has so far received an extra $765 million of a targeted $2 billion in funding for Covid-19 vaccine development from multiple governments. The Biomedical Advanced Research and Development Authority, part of the US Department of Health and Human Services, has invested substantially in vaccine-development projects with Johnson & Johnson ($450 million) and Moderna ($483 million). And the European Union intends to mobilise further public funding to tackle the pandemic at an online pledging conference on May 4th.

Cutting-edge thinking straight to your inbox

"Social Europe publishes thought-provoking articles on the big political and economic issues of our time analysed from a European viewpoint. Indispensable reading!"

Polly Toynbee

Columnist for The Guardian

Thank you very much for your interest! Now please check your email to confirm your subscription.

There was an error submitting your subscription. Please try again.

Powered by ConvertKit

But investment alone is not enough. To succeed, the entire vaccine-innovation process, from research and development to access, must be governed by clear and transparent rules of engagement based on public-interest goals and metrics. That, in turn, will require a clear alignment between global and national public interests.

Mission-oriented approach

The first, critical step is to adopt a mission-oriented approach that focuses both public and private investments on achieving a clearly defined common goal: developing an effective Covid-19 vaccine(s) that can be produced at global scale rapidly and made universally available for free. Realizing this aim will require firm rules regarding intellectual property (IP), pricing and manufacturing, designed and enforced in ways that value international collaboration and solidarity, rather than competition between countries.

Secondly, to maximise the impact on public health, the innovation ecosystem must be steered to use collective intelligence to accelerate advances. Science and medical innovation thrives and progresses when researchers exchange and share knowledge openly, enabling them to build upon one another’s successes and failures in real time.

But today’s proprietary science does not follow that model. Instead, it promotes secretive competition, prioritises regulatory approval in wealthy countries over wide availability and global public-health impact, and erects barriers to technological diffusion. And, although voluntary intellectual-property pools like the one that Costa Rica has proposed to the World Health Organization can be helpful, they risk being ineffective as long as private, for-profit companies are allowed to retain control over critical technologies and data—even when these were generated with public investments.


Please help us improve public policy debates


As you may know, Social Europe is an independent publisher. We aren't backed by a large publishing house or big advertising partners. For the longevity of Social Europe we depend on our loyal readers - we depend on you. You can support us by becoming a Social Europe member for less than 5 Euro per month.

Thank you very much for your support!

Become a Social Europe Member

Moreover, collective steering is vital to select and pursue the most promising potential vaccines. Otherwise, marketing authorisation may go to the best-resourced candidate rather than the most suitable one.

Capacity and infrastructure

Thirdly, countries must take the lead in building and buttressing manufacturing capabilities, particularly in the developing world. While an effective Covid-19 vaccine probably will not be available for another 12-18 months, a concerted effort is needed now to put in place the public and private capacity and infrastructure needed to produce rapidly the billions of doses that will be required.

Because we don’t know yet which vaccine will prove most effective, we may need to invest in a range of assets and technologies. This poses a technological and financial risk that can be overcome only with the help of entrepreneurial states backed by collective, public-interest-driven financing, such as from national and regional development banks, the World Bank and philanthropic foundations.

Finally, conditions for ensuring global, equitable and affordable access must be built into any vaccine-development programme from the start. This would allow public investments to be structured less like a handout or simple market-fixer, and more like a proactive market-shaper, driven by public objectives.

Pricing of Covid-19 vaccines should reflect both the substantial public contribution to their development and the urgency and magnitude of the global health crisis. We must go beyond statements of principle and generic pledges, and introduce concrete conditions that enable vaccines to be free at the point of use. Policy-makers should also consider using compulsory licensing to allow countries to make the best use of the available tools and technologies.

Crucially, we need collective procurement mechanisms that ensure fair allocation and equitable global access to the new vaccines as they become available. The overriding goal must be to prevent advanced economies from monopolising the global supply or crowding out demand from poorer countries.

Public interest

The Covid-19 crisis rules out a business-as-usual approach. As countries mobilise collectively against the pandemic through calls for a global alliance, pledging conferences, G20 meetings and the upcoming annual World Health Assembly, we cannot afford to miss this chance. These collective efforts must include clear and enforceable rules of engagement that commit all partners to an end-to-end approach to health innovation based on the public interest—an effective Covid-19 vaccine that can be rapidly made available to all for free.

Developing an effective and universally available Covid-19 vaccine is one of the most critical missions of our lifetime. Above all, it is a litmus test of whether global public-private co-operation, touted by policy-makers as the key to success, will maximise the supply of public goods or the share of private profits.

Republication forbidden—copyright Project Syndicate 2020, ‘How to develop a Covid-19 vaccine for all’

Share on TwitterShare on FacebookShare on LinkedIn
Home ・ How to develop a Covid-19 vaccine for all

Filed Under: Politics Tagged With: coronavirus

About Mariana Mazzucato and Els Torreele

Mariana Mazzucato is professor of the economics of innovation and public value and director of the University College London Institute for Innovation and Public Purpose (IIPP); she is author of The Value of Everything: Making and Taking in the Global Economy (Allen Lane, 2019). Els Torreele is executive director of the Médecins Sans Frontières Access Campaign.

Partner Ads

Most Popular Posts

decarbonisation,energy transition Europe’s decarbonisation challenge? ‘Wir schaffen das’ Adam Tooze
integrated review Lost an empire, not found a role Paul Mason
Uber v Aslam,UK Supreme Court Putting the brakes on the spread of indecent work Ruth Dukes and Wolfgang Streeck
debt cancellation,cancellation of debt,ECB Cancelling a debt we already own has a false allure Anne-Laure Delatte, Michel Husson, Benjamin Lemoine, Éric Monnet, Raul Sampognaro, Bruno Tinel and Sébastien Villemot
horizontal inequalities,vertical inequalities Fissures that tear us apart and pressures that weigh us all down Kate Pickett

Other Social Europe Publications

RE No. 12: Why No Economic Democracy in Sweden?
US election 2020
Corporate taxation in a globalised era
The transformation of work
The coronavirus crisis and the welfare state

Social Europe Publishing book

With a pandemic raging, for those countries most affected by Brexit the end of the transition could not come at a worse time. Yet, might the UK's withdrawal be a blessing in disguise? With its biggest veto player gone, might the European Pillar of Social Rights take centre stage? This book brings together leading experts in European politics and policy to examine social citizenship rights across the European continent in the wake of Brexit. Will member states see an enhanced social Europe or a race to the bottom?

'This book correctly emphasises the need to place the future of social rights in Europe front and centre in the post-Brexit debate, to move on from the economistic bias that has obscured our vision of a progressive social Europe.' Michael D Higgins, president of Ireland


MORE INFO

Hans Böckler Stiftung Advertisement

Renewing labour relations in the German meat industry: an end to 'organised irresponsibility'?

Over the course of 2020, repeated outbreaks of Covid-19 in a number of large German meat-processing plants led to renewed public concern about the longstanding labour abuses in this industry. New legislation providing for enhanced inspection on health and safety, together with a ban on contract work and limitations on the use of temporary agency employees, holds out the prospect of a profound change in employment practices and labour relations in the meat industry. Changes in the law are not sufficient, on their own, to ensure decent working conditions, however. There is also a need to re-establish the previously high level of collective-bargaining coverage in the industry, underpinned by an industry-wide collective agreement extended by law to cover the entire sector.


FREE DOWNLOAD

ETUI advertisement

Social protection during the pandemic: freelancers in the creative industries

This working paper identifies some key areas of policy intervention for advancing socially sustainable and fair solutions for freelancers working in the creative industries, who are among those who have suffered the most from the economic fallout of the Covid-19 pandemic. In particular, the authors focus on those who work entirely on their own account, without employees (ie the ‘solo self-employed’), and who undertake project- or task-based work on a fixed-term basis.


DOWNLOAD HERE

Eurofound advertisement

Industrial relations: developments 2015-2019

Eurofound has monitored and analysed developments in industrial relations systems at EU level and in EU member states for over 40 years. This new flagship report provides an overview of developments in industrial relations and social dialogue in the years immediately prior to the Covid-19 outbreak. Findings are placed in the context of the key developments in EU policy affecting employment, working conditions and social policy, and linked to the work done by social partners—as well as public authorities—at European and national levels.


CLICK FOR MORE INFO

Foundation for European Progressive Studies Advertisement

#Care4Care!

It took us a global pandemic to realise that we depend on care. Despite all the clapping from the balconies, care workers continue to work in precarious and vulnerable conditions. Women, who represent 70% of the care workforce, continue to suffer from a severe lack of recognition for both their paid and unpaid care work. It’s time for a care revolution! It’s time to #Care4Care! The Foundation for European Progressive Studies (FEPS), together with the Friedrich-Ebert-Stiftung (FES), has been intensively working since 2019 to monitor the EU gender equality policy agenda through a progressive lens focusing particularly on its care dimensions.


FIND OUT MORE HERE

About Social Europe

Our Mission

Article Submission

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Find Social Europe Content

Search Social Europe

Project Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

.EU Web Awards